$四環醫藥.HK公布，日前出席於美國芝加哥舉行的第 59 屆美國臨床腫瘤學會 (ASCO)，會上展示了旗下軒竹生物自主研發的創新型 CDK4/6 抑制劑吡羅西尼單藥治的療多線治療 (包括內分泌治療和化療) 後進展的 HR+/HER2-轉移性乳腺癌的良好療效。
該抑制劑是是內地首個進行單藥末線註冊性臨床試驗的 CDK4/6 抑制劑。集團指，有望在未來探索該重磅產品價值最大化，乳腺癌賽道龐大的市場空間和優異的產品療效，令該藥能快速搶佔市場，助力公司發展全速前進。
Traded Value
OrdersThe copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Like